FTC/TDF For HIV PrEP Highly Effective, Study Finds

Infectious Disease Advisor (5/22, Chan) reports, “The use of emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) for HIV pre-exposure prophylaxis (PrEP) is highly effective across diverse populations, geographies, and routes of HIV exposure.” Additionally, “this PrEP combination is effective when administered less than once daily.” In a study of 17,274 patients, “overall, 101 patients developed HIV Infection after PrEP initiation or within 60 days of discontinuation (incidence rate [IR], 0.77; 95% CI, 0.63-0.94).” The results were published in Clinical Infectious Diseases.